Torrent Pharmaceuticals Ltd. — M&A Activity 2021

Apr 1, 2021

==> picture [108 x 26] intentionally omitted <==

September	9,2015
Sr. No.	Particulars	Detail
a.	Nameofthe target entity, details inbriefsuch as size, turnover etc.	(i)Nameofthe Target Entity:Pharmarack Technologies Private Limited("Pharmarack").(ii)Detailsofthe Target Entity:Phannarack operates a digital platformaimed at integrating and solving problemsacross the pharmaceutical supply chain. Itsplatform offers/ proposes to offer productsacross supply chain including orderautomation, fulfilment services &optimization, digital payments, workingcapital optimization, analytics and marketinsights.
b.	Whether the acquisition would fall withinNota related party transactionrelated patty transaction(s)and whether1thepromoter/promoter group/ groupIcompanies have any interest in the entity ,being acquired?Ifyes, natureofinterestand detailsthereofand whether the sameisone at "arms-length"
C.	Industry to which the entity beingacquired belongs	Healthcare Industry
d.	Objectsandeffectsofacquisition(including but not limited to, disclosureofreasons for acquisitionoftarget entity,ifits businessisoutside the main line'ofbusinessofthe listed entity)	IA step by ABCD Technologies LLP (to berenamed as IndoHealth Services LLP)towards the initiative with an objectivetofacilitate, enable and promote efficiency and. Good Distribution Practices**('GDP')including digitizing healthcare infrastructurein India, inter alia, in supportofthe NationalDigital Health MissionofGovernmentofIndia('Business').**Theacquisitionisand willbe done by its wholly owned entityDigiHealth Technologies LLP.~

==> picture [56 x 26] intentionally omitted <==

		m;orrwPHRR
e.Briefdetailsofanygovernmentalorregulatory approvals required fortheacquisition		NotApplicable
f.	Indicativetimeperiod forcompletionofthe acqui~itionI	I'he upfront acquisitionof91.8%ofshareholdinginPharmarackisexpectedtobecompletedwithin a periodof30(thi1iy)daysbypurchaseofshares frommultipleexisting shareholders in various lots.Theremaining8.2%oftheshareholdinginPharmarackis likelytobe acquired inmultiple tranchesoverthenext 5 (five)years.
g.	Natureofconsideration- whethercashconsiderationorshareswapanddetailsofthesame	CashConsiderationpayablebyDigiHealthTechnologiesLLP.
h.	Costofacquisitionortheprice atwhichtheshares areacquired	CostofacquisitiontoDigiHealthTechnologiesLLPforupfrontacquisitionof91.8%isINR111 crores.I.Costofacquisitionofremainingshareholdingshallbelinked to futureperformanceofPharmarack.
I.	Percentageofshareholding~~_7_~~control acquiredand/ornumberofshares acquired	Pleaserefer totheresponseprovided inpoint(f) above.
J.	Briefbackgroundabouttheentityacquired111termsofproducts/lineofbusiness acquired, dateofincorporation,historyoflast 3 years turnover, country inwhichtheacquired entity haspresenceandanyothersignificant information (inbrief)	(i)About the entity:Pharmarackoperatesa digitalplatformaimedatintegratingandsolvingproblemsacrossthepharmaceuticalsupplychain.Itsplatformoffers/proposestoofferproducts acrosssupplychainincludingorderautomation,fulfilmentservices&optimization,digitalpayments,workingcapitaloptimization,analyticsandmarketinsights.(ii)**DateofIncorporation:**September21,2015(iii)Turnover historyoflast 3 years:

==> picture [57 x 28] intentionally omitted <==

==> picture [91 x 39] intentionally omitted <==